Neide Griebeler will present research with promising results during the 47th edition of SBNeC
For more than four decades, important names in neuroscience have gathered annually at the Meeting of the Brazilian Society of Neuroscience and Behavior (SBNeC) to participate in conferences, courses, symposia, round tables, thematic modules and panels presented throughout the event.
In the 2024 edition, which will take place between October 28 and November 1, in the city of Águas de Lindóia-SP, SBNeC will feature the participation of veterinarian and researcher from the Federal University of Latin American Integration (UNILA), Neide Griebeler, one of those selected to present her project during the event.
Neide developed research with promising results to analyze the effectiveness of cannabis in reducing pain in dogs with osteoarthritis. According to her, even though it is an event focused on human neurology, the experience will be extremely enriching. "In addition to adding to my knowledge, this moment brings greater visibility to cannabis and its therapeutic potential," reports the veterinarian.
Cannabis in the fight against osteoarthritis
During her master´s degree, over the course of 90 days, the researcher evaluated 17 animals divided into two groups (treatment and placebo) to verify the efficacy and safety of using a full-spectrum Cannabis sativa extract.
The research found a significant reduction in the intensity of pain in dogs with osteoarthritis that received cannabis, with pain scores falling from 16.22 to 5.71 points. In the placebo group, the reduction was smaller, going from 16.22 to 12.85 points.
In addition, a significant improvement was observed in pain interference, chronic pain index, veterinary evaluation and the quality of life of the animals. At the beginning of the study, 33.33% of the dogs in the cannabis-treated group were classified as having a “poor” quality of life, while in the placebo group, this percentage was 37.50%. After 90 days, no dog in the cannabis group was classified as “very poor”, while in the placebo group this rate was 28.57%.
In addition, 28.6% of the dogs in the cannabis-treated group were classified as having an “excellent” quality of life at the end of the study, compared to 14.28% in the placebo group. The “very good” quality of life, which was 0% at the beginning for the cannabis-treated group, rose to 14.28%, demonstrating a significant improvement in relation to the placebo group.
Source: https://sechat.com.br/noticia/estudo-sobre-uso-de-cannabis-para-tratar-osteoartrite-em-caes-sera-destaque-em-renomado-evento-de-neurociencias
Study on the use of cannabis to treat osteoarthritis in dogs will be highlighted at renowned neuroscience event
